ARTICLE | Top Story
Eli Lilly in-licenses Incyte's INCB28050
December 22, 2009 1:47 AM UTC
Incyte Corp. (NASDAQ:INCY) granted Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to develop and commercialize INCB28050 and follow-on compounds for inflammatory and autoimmune diseases. The...